Last reviewed · How we verify
Flucelvax Quad
At a glance
| Generic name | Flucelvax Quad |
|---|---|
| Sponsor | Codagenix, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (PHASE3)
- Intramuscular CodaVax-H1N1 in Healthy Adults (PHASE1)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. (PHASE2)
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older (PHASE1, PHASE2)
- Phase 3 Pivotal Trial of NanoFlu™ in Older Adults (PHASE3)
- Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flucelvax Quad CI brief — competitive landscape report
- Flucelvax Quad updates RSS · CI watch RSS
- Codagenix, Inc portfolio CI